With bids due today, Solvay mulls options

Will Solvay--or won't it? Preliminary offers for its pharmaceutical unit are due today, Reuters reports, which means we could know fairly soon whether the Belgian company will go ahead with a sale. Solvay hired Citigroup to take a look at various options for its pharma unit; everything from growing the business via acquisitions to selling it off completely.

And you'll recall that Sanofi-Aventis reportedly approached Solvay about buying the pharma business. Among other interested parties, sources tell Reuters, is Novartis. Analysts tagged Bayer as another potential buyer. Companies that aren't bidding: Abbott Laboratories, Solvay's TriCor partner; and Takeda Pharmaceutical, which denied reports that it was interested in a deal.

Another question appears to be whether Solvay will be broken up for sale or go to one buyer lock, stock and barrel. The company has a flu-vaccine business--Solvay Biologicals--that could be very attractive to some buyers, especially in the midst of a global outbreak of novel flu, the news service said.

- read the Reuters story
- check out Takeda's denial of interest, also from Reuters

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.